Home › Companies › IDEAYA Biosciences, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and IDEAYA Biosciences, Inc.’s Form 8-K, filed June 23, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 16, 2026: 5 items on IDEAYA Biosciences, Inc.’s Form 8-K, filed June 23, 2026: 5 passed (calculated).
Significant dissent: 1 director (22.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore IDEAYA Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are IDEAYA Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 23, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Yujiro S. Hata | 70,546,418 | -- | -- | 2,470,077 | 10,089,343 | 97% | Passed (calculated) | — |
| Elect Director: M. Garret Hampton, Ph.D. | 56,718,637 | -- | -- | 16,297,858 | 10,089,343 | 78% | Passed (calculated) | — |
| Elect Director: Catherine J. Mackey, Ph.D. | 70,281,521 | -- | -- | 2,734,974 | 10,089,343 | 96% | Passed (calculated) | — |
| 2. The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2026 | 82,579,758 | 141,240 | 384,840 | -- | -- | 99.8% | Passed (calculated) | — |
| 3. Non-binding, advisory vote to approve the compensation of the Company's named executive officers | 64,269,756 | 8,349,131 | 397,608 | -- | 10,089,343 | 89% | Passed (calculated) | — |
Source: IDEAYA Biosciences, Inc., Form 8-K, filed with the SEC on June 23, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
286 asset managers disclosed a vote on at least one IDEAYA Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Catherine J. Mackey, Ph.D.
IDEAYA Biosciences, Inc.’s own tally for this item (“Elect Director: Catherine J. Mackey, Ph.D.”): 70,281,521 for, 2,734,974 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 32,881,085 for, 550,344 withheld, 9 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,288,041 | 0 | 0 | 0 | For |
| Capital Group | 5,163,543 | 0 | 0 | 0 | For |
| Vanguard | 4,453,982 | 0 | 9 | 0 | For |
| BlackRock | 3,230,366 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,156,609 | 0 | 0 | 0 | For |
| State Street | 1,648,817 | 0 | 0 | 0 | For |
| Federated Hermes | 1,431,630 | 0 | 0 | 0 | For |
| T. Rowe Price | 904,596 | 0 | 0 | 0 | For |
| Charles Schwab | 718,071 | 0 | 0 | 0 | For |
| TIAA | 701,310 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 447,090 | Withhold |
| GENERAL AMERICAN INVESTORS CO INC | 301,057 | 0 | 0 | 0 | For |
| Victory Capital | 300,956 | 0 | 0 | 0 | For |
| First Trust | 275,294 | 0 | 0 | 0 | For |
| Goldman Sachs | 248,318 | 0 | 0 | 0 | For |
| American Century | 242,229 | 0 | 0 | 0 | For |
| Equitable | 127,433 | 0 | 0 | 68,180 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 137,423 | 0 | 0 | 0 | For |
| New York Life | 133,863 | 0 | 0 | 0 | For |
| Jackson National | 112,404 | 0 | 0 | 16,326 | Mixed |
| Tema ETF Trust | 128,546 | 0 | 0 | 0 | For |
| JPMorgan | 119,428 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 81,852 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 70,780 | 0 | 0 | 0 | For |
| Russell Investments | 61,680 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: M. Garret Hampton, Ph.D.
IDEAYA Biosciences, Inc.’s own tally for this item (“Elect Director: M. Garret Hampton, Ph.D.”): 56,718,637 for, 16,297,858 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 31,284,057 for, 2,143,547 withheld, 3,834 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,288,041 | 0 | 0 | 0 | For |
| Capital Group | 5,163,543 | 0 | 0 | 0 | For |
| Vanguard | 4,449,943 | 0 | 48 | 4,001 | For |
| BlackRock | 3,230,366 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,076,415 | 0 | 0 | 80,194 | For |
| State Street | 1,646,922 | 0 | 0 | 1,895 | For |
| Federated Hermes | 1,431,630 | 0 | 0 | 0 | For |
| T. Rowe Price | 904,596 | 0 | 0 | 0 | For |
| Charles Schwab | 718,071 | 0 | 0 | 0 | For |
| TIAA | 701,310 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 447,090 | Withhold |
| GENERAL AMERICAN INVESTORS CO INC | 301,057 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 300,956 | Withhold |
| First Trust | 0 | 0 | 0 | 275,294 | Withhold |
| Goldman Sachs | 248,318 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 242,229 | Withhold |
| Equitable | 127,433 | 0 | 0 | 68,180 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 137,423 | 0 | 0 | 0 | For |
| New York Life | 133,863 | 0 | 0 | 0 | For |
| Jackson National | 112,404 | 0 | 0 | 16,326 | Mixed |
| Tema ETF Trust | 128,546 | 0 | 0 | 0 | For |
| JPMorgan | 119,428 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 81,852 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 70,780 | Withhold |
| Russell Investments | 0 | 0 | 0 | 61,680 | Withhold |
Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Yujiro S. Hata
IDEAYA Biosciences, Inc.’s own tally for this item (“Elect Director: Yujiro S. Hata”): 70,546,418 for, 2,470,077 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 32,881,087 for, 550,344 withheld, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,288,041 | 0 | 0 | 0 | For |
| Capital Group | 5,163,543 | 0 | 0 | 0 | For |
| Vanguard | 4,453,984 | 0 | 7 | 0 | For |
| BlackRock | 3,230,366 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,156,609 | 0 | 0 | 0 | For |
| State Street | 1,648,817 | 0 | 0 | 0 | For |
| Federated Hermes | 1,431,630 | 0 | 0 | 0 | For |
| T. Rowe Price | 904,596 | 0 | 0 | 0 | For |
| Charles Schwab | 718,071 | 0 | 0 | 0 | For |
| TIAA | 701,310 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 447,090 | Withhold |
| GENERAL AMERICAN INVESTORS CO INC | 301,057 | 0 | 0 | 0 | For |
| Victory Capital | 300,956 | 0 | 0 | 0 | For |
| First Trust | 275,294 | 0 | 0 | 0 | For |
| Goldman Sachs | 248,318 | 0 | 0 | 0 | For |
| American Century | 242,229 | 0 | 0 | 0 | For |
| Equitable | 127,433 | 0 | 0 | 68,180 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 137,423 | 0 | 0 | 0 | For |
| New York Life | 133,863 | 0 | 0 | 0 | For |
| Jackson National | 112,404 | 0 | 0 | 16,326 | Mixed |
| Tema ETF Trust | 128,546 | 0 | 0 | 0 | For |
| JPMorgan | 119,428 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 81,852 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 70,780 | 0 | 0 | 0 | For |
| Russell Investments | 61,680 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).
Combines 12 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Prior year: 77.8% for (June 24, 2025 meeting) ▲ 10.7 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; and
IDEAYA Biosciences, Inc.’s own tally for this item (“3. The non-binding, advisory vote to approve the compensation of the Company's named executive officers”): 64,269,756 for, 8,349,131 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,288,041 | 0 | 0 | 0 | For |
| Capital Group | 0 | 5,163,543 | 0 | 0 | Against |
| Vanguard | 4,453,982 | 9 | 1 | 0 | For |
| BlackRock | 3,230,366 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,156,609 | 0 | 0 | 0 | For |
| State Street | 1,648,134 | 683 | 0 | 0 | For |
| Federated Hermes | 1,431,630 | 0 | 0 | 0 | For |
| T. Rowe Price | 904,596 | 0 | 0 | 0 | For |
| Charles Schwab | 718,071 | 0 | 0 | 0 | For |
| TIAA | 701,310 | 0 | 0 | 0 | For |
| Dimensional | 447,090 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 301,057 | 0 | 0 | 0 | For |
| Victory Capital | 300,956 | 0 | 0 | 0 | For |
| First Trust | 275,294 | 0 | 0 | 0 | For |
| Goldman Sachs | 248,318 | 0 | 0 | 0 | For |
| American Century | 0 | 242,229 | 0 | 0 | Against |
| Equitable | 195,613 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,423 | 0 | 0 | 0 | For |
| New York Life | 133,863 | 0 | 0 | 0 | For |
| Jackson National | 128,730 | 0 | 0 | 0 | For |
| Tema ETF Trust | 128,546 | 0 | 0 | 0 | For |
| JPMorgan | 119,428 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 81,852 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 70,780 | 0 | 0 | 0 | For |
| Russell Investments | 61,680 | 0 | 0 | 0 | For |
Fund voting reports, all 72 managers: 27,992,585 for, 5,444,088 against, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 13,520,075 | 0 | 0 | 0 | For |
| Fidelity | 13,171,821 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 5,163,543 | 0 | 0 | Against |
| BlackRock | 3,654,365 | 37,992 | 0 | 0 | For |
| Logos Global Management LP | 3,299,287 | 0 | 0 | 0 | For |
| State Street | 2,994,456 | 17,194 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,281,996 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1,684,401 | 0 | 0 | 0 | For |
| Federated Hermes | 1,431,630 | 0 | 0 | 0 | For |
| Fiera Capital Corp | 1,300,996 | 78,024 | 0 | 0 | Mixed |
| T. Rowe Price | 1,349,483 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 1,231,368 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 998,708 | 0 | 0 | Against |
| Ensign Peak Advisors, Inc | 899,504 | 0 | 0 | 0 | For |
| Charles Schwab | 719,836 | 0 | 0 | 0 | For |
| Nuveen | 713,678 | 0 | 0 | 0 | For |
| Vanguard | 687,548 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 641,134 | 0 | 0 | 0 | For |
| Aberdeen | 618,436 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 544,800 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 476,740 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 455,017 | 0 | 0 | 0 | For |
| Northern Trust | 418,395 | 9,484 | 0 | 0 | For |
| Fisher Asset Management, LLC | 403,053 | 6,704 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 368,545 | 0 | 0 | 0 | For |
Institutional-manager reports, all 232 managers: 57,942,332 for, 7,066,904 against, 24,284 abstained, 258 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Prior year: 99.7% for (June 24, 2025 meeting) ▲ 0.1 pts
Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026;
IDEAYA Biosciences, Inc.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending”): 82,579,758 for, 141,240 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 33,436,605 for, 632 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,288,041 | 0 | 0 | 0 | For |
| Capital Group | 5,163,543 | 0 | 0 | 0 | For |
| Vanguard | 4,453,990 | 0 | 1 | 0 | For |
| BlackRock | 3,230,366 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,156,609 | 0 | 0 | 0 | For |
| State Street | 1,648,752 | 65 | 0 | 0 | For |
| Federated Hermes | 1,431,630 | 0 | 0 | 0 | For |
| T. Rowe Price | 904,596 | 0 | 0 | 0 | For |
| Charles Schwab | 718,071 | 0 | 0 | 0 | For |
| TIAA | 701,310 | 0 | 0 | 0 | For |
| Dimensional | 447,090 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 301,057 | 0 | 0 | 0 | For |
| Victory Capital | 300,956 | 0 | 0 | 0 | For |
| First Trust | 275,294 | 0 | 0 | 0 | For |
| Goldman Sachs | 248,318 | 0 | 0 | 0 | For |
| American Century | 242,229 | 0 | 0 | 0 | For |
| Equitable | 195,613 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,423 | 0 | 0 | 0 | For |
| New York Life | 133,863 | 0 | 0 | 0 | For |
| Jackson National | 128,730 | 0 | 0 | 0 | For |
| Tema ETF Trust | 128,546 | 0 | 0 | 0 | For |
| JPMorgan | 119,428 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 81,852 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 70,780 | 0 | 0 | 0 | For |
| Russell Investments | 61,680 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 87,856,154 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 10.57% |
| 2 | Capital Group | 5.88% |
| 3 | Vanguard | 5.07% |
| 4 | BlackRock | 3.68% |
| 5 | JANUS INVESTMENT FUND | 2.45% |
| 6 | State Street | 1.88% |
| 7 | Federated Hermes | 1.63% |
| 8 | T. Rowe Price | 1.03% |
| 9 | Charles Schwab | 0.82% |
| 10 | TIAA | 0.80% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 15.39% |
| 2 | Fidelity | 14.99% |
| 3 | Capital Research Global Investors | 5.88% |
| 4 | BlackRock | 4.20% |
| 5 | Logos Global Management LP | 3.76% |
| 6 | State Street | 3.43% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.60% |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1.92% |
| 9 | Federated Hermes | 1.63% |
| 10 | Fiera Capital Corp | 1.57% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 13,172,103 | 14.99% | Form 13F, quarter ended March 31, 2026 |
| FMR LLC | 12,635,652 | 14.38% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| BlackRock | 8,442,133 | 9.61% | Form 13F, quarter ended March 31, 2026 |
| JANUS HENDERSON GROUP PLC | 7,265,253 | 8.27% | Schedule 13G, filed May 15, 2026 |
| Capital Research Global Investors | 5,279,675 | 6.01% | Schedule 13G, filed February 12, 2026 |
| Vanguard Group | 5,019,324 | 5.71% | Form 13F, quarter ended March 31, 2026 |
| State Street | 3,781,167 | 4.30% | Form 13F, quarter ended March 31, 2026 |
| Federated Hermes, Inc. | 3,395,771 | 3.87% | Schedule 13G, filed January 8, 2026 |
| Goldman Sachs | 1,913,617 | 2.18% | Form 13F, quarter ended March 31, 2026 |
| Point72 Asset Management, L.P. | 1,844,556 | 2.10% | Schedule 13G, filed February 17, 2026 |
Percentages above are of 87,856,154 shares outstanding, as reported by IDEAYA Biosciences, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At IDEAYA Biosciences, Inc.'s shareholder meeting held June 16, 2026, in the 2025-2026 proxy season, 286 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,543 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 89% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: IDEAYA Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 23, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IDEAYA Biosciences, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
IDEAYA Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “IDEAYA Biosciences (IDYA) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ideaya-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.